论文部分内容阅读
目的:探索LINC01836和结直肠癌之间的关系。方法:通过癌症基因组图谱（The Cancer Genome Atlas，TCGA）数据库进行回顾性研究。在TCGA数据库下载2020年4月7日发布的V23.0版本的结直肠癌患者基因表达谱数据，通过Wilcoxon秩和检验、卡方检验、Fisher检验和logistic回归分析评估临床病理特征与LINC01836表达之间的关系。绘制受试者工作特征曲线（receiver operating characteristic curve，ROC）用于评价LINC01836对结直肠癌的诊断价值。Kaplan-Meier生存分析用于评估LINC01836对结直肠癌患者预后的影响。结果:结直肠癌中LINC01836表达在不同的N分期（n χ2=6.68，n P=0.035）、M分期（n χ2=9.32，n P=0.002）、病理分期（n χ2=12.60，n P<0.001）、淋巴侵犯（n χ2=11.82，n P<0.001）和结肠息肉（n χ2=4.51，n P=0.034）的差异均有统计学意义。logistics回归分析结果显示：高表达的LINC01836与N分期进展（n OR=1.469，n P=0.017）、M分期进展（n OR=2.131，n P=0.002）、病理分期进展（n OR=1.580，n P=0.005）、淋巴侵犯（n OR=1.826，n P<0.001）、结肠息肉相关（n OR=0.576，n P=0.025）。ROC表明LINC01836对区分结直肠癌组织与癌旁正常组织［曲线下面积（AUC）=0.907］和正常组织（AUC=0.899）均具有显著的诊断效能。Kaplan-Meier生存分析表明，LINC01836高表达与结直肠癌患者总体生存率低有关（n P=0.002）。n 结论:LINC01836在结直肠癌组织中高表达，并与结直肠癌患者多种临床病理特征相关，可能成为结直肠癌新的有潜在应用价值的生物标志物。“,”Objective:To explore the relationship between LINC01836 and colorectal cancer.Methods:A retrospective study was performed through the Cancer Genome Atlas (TCGA) database. The V23.0 gene expression profile data of colorectal cancer patients released on April 7, 2020 in the TCGA database were downloaded. The relationship between clinicopathological features and LINC01836 expression was evaluated by Wilcoxon rank sum test, chi square test, Fisher test, and logistic regression analysis. Receiver operating characteristic curve (ROC) was drawn to evaluate the diagnostic value of LINC01836 for colorectal cancer. Kaplan-Meier survival analysis was used to evaluate the effect of LINC01836 on the prognosis of patients with colorectal cancer.Results:The expression of LINC01836 in colorectal cancer was statistically different in different N stage (n χ2=6.68, n P=0.035), M stage (n χ2=9.32, n P=0.002), pathological stage (n χ2=12.6, n P<0.001), lymphatic invasion (n χ2=11.82, n P<0.001), and colonic polyps (n χ2=4.51, n P=0.034). Logistic regression showed that the high expression of LINC01836 was associated with N stage progression (n OR=1.469,n P = 0.017), M stage progression (n OR=2.131, n P=0.002), pathological stage progression (n OR=1.580, n P=0.005), lymphatic invasion (n OR=1.826,n P<0.001), and colonic polyps (n OR=0.576, n P=0.025). ROC showed that LINC01836 had significant diagnostic efficacy in distinguishing colorectal cancer tissues from adjacent normal tissue [area under curve (AUC)=0.907] and normal tissue (AUC=0.899). Kaplan-Meier survival analysis showed that the high expression of LINC01836 was associated with the low overall survival rate in the patients with colorectal cancer (n P=0.002).n Conclusions:LINC01836 is highly expressed in colorectal cancer and is related to a variety of clinicopathological features of colorectal cancer patients. It may become a new biomarker with potential application value for colorectal cancer.